Mnk2b Antibody

Product Specifications

Background

MAP kinase-interacting kinases Mnk1 and Mnk2, are activated by the MAP kinases, ERK and p38 (Waskiewicz et al., 1997) . Additionally, Mnk1 and Mnk2 have been shown to phosphorylate the translation initiation factor eIF4E (Fukunaga and Hunter 1997; Waskiewicz et al., 1997) . Alternative splicing of the MKNK2 gene results in two isoforms with different C-termini: one that has a MAPK-binding domain, Mnk2a, and one that does not, Mnk2b (Parra et al., 2005) . Recent studies have indicated that Mnk2a has tumor suppressive activity while Mnk2b is pro-oncogenic (Maimon et al., 2014) .

Synonyms

MADS box transcription enhancer factor 2 antibody, MDS1 EVI1 antibody, Mef2b antibody, MEF2B_HUMAN antibody, Myocyte enhancer factor 2B antibody, Myocyte specific enhancer factor 2B antibody, Myocyte-specific enhancer factor 2B antibody, PRDM3 antibody, RSRFR2 antibody, whole antiserum response factor like protein 2 antibody, whole antiserum response factor-like protein 2 antibody, XMEF2 antibody

Gene ID

2872

Swiss Prot

Q9HBH9

Host

Rabbit

Cross Reactivity

Human

Target

Mnk2b

Clonality

Polyclonal

Isotype

IgG

Conjugation

Unconjugated

Source

Synthetic peptide from the C-terminal region, specific to the human Mnk2b isoform. The sequence of the antigen has no homology with Mnk1 or Mnk2a.

Applications

Purification

Antigen Affinity purification from Pooled whole antiserum

Concentration

Lot Dependent

Dilution

WB (1:300-5000)

Buffer

10 mM HEPES (pH 7.5), 150 mM NaCl, 100 µg per ml BSA and 50% glycerol.

Modification

Unmodified

Storage Conditions

Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C.

Specificity

Specific for endogenous levels of the ~47 kDa Mnk2b protein. Immunolabeling is blocked by preadsorption with the Mnk2b peptide used as antigen, but not by Mnk2a peptide.